|Articles|October 1, 2000

October 2000
Volume 6
Issue 10

Therapeutic Substitution of Cimetidine for Nizatidine Was Not Associated with an Increase in Healthcare Utilization

Author(s)Chester B. Good, MD, MPH, Shawn L. Fultz, MD, Lauren Trilli, PharmD

Download PDF: Therapeutic Substitution of Cimetidine for Nizatidine Was Not Associated with an Increase in Healthcare Utilization

Articles in this issue

almost 26 years ago

Article

A Comparison of Medicare Fee-for-Service and a Group-Model HMO in the Inpatient Management and Long-Term Survival of Elderly Individuals with Syncope

almost 26 years ago

Article

Follow-Up Among Women with an Abnormal Mammogram in an HMO: Is It Timely, Complete, and Efficient?

almost 26 years ago

Article

Accrediting Organizations and Quality Improvement

almost 26 years ago

Article

Efficient Evaluation of Thyroid Nodules by Primary Care Providers and Thyroid Specialists

almost 26 years ago

Article

Diagnosis of Skin Disease by Nondermatologists

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Therapeutic Substitution of Cimetidine for Nizatidine Was Not Associated with an Increase in Healthcare Utilization

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Jeff Hunnicutt to Bring Community Oncology Roots to New Role as Navista COO

New MINT Trial Analysis Favors Liberal Transfusion After MI

Contributor: State Leaders Need Real-World Evidence to Integrate Social Care at Scale

Nipocalimab Improves gMG Outcomes Across East Asian Subgroup

Drug Development-to-Reimbursement Timelines Show Little Progress Over a Decade